Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3083
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rajam, Gowrisankar | en |
dc.contributor.author | Tzanakaki, Georgina | en |
dc.contributor.author | Vadivelu-Pechai, Kumaran | en |
dc.contributor.author | Watson, Philip | en |
dc.contributor.author | Vazquez, Julio A. | en |
dc.contributor.author | Rappuoli, Rino | en |
dc.contributor.author | Medini, Duccio | en |
dc.contributor.author | Borrow, Ray | en |
dc.contributor.author | Muzzi, Alessandro | en |
dc.contributor.author | Brozzi, Alessandro | en |
dc.contributor.author | Serino, Laura | en |
dc.contributor.author | Bodini, Margherita | en |
dc.contributor.author | Abad, Raquel | en |
dc.contributor.author | Caugant, Dominique | en |
dc.contributor.author | Comanducci, Maurizio | en |
dc.contributor.author | Lemos, Ana Paula | en |
dc.contributor.author | Gorla, Maria Cecilia | en |
dc.contributor.author | Křížová, Pavla | en |
dc.contributor.author | Mikula, Claudia | en |
dc.contributor.author | Mulhall, Robert | en |
dc.contributor.author | Nissen, Michael | en |
dc.contributor.author | Nohynek, Hanna | en |
dc.contributor.author | Simões, Maria João | en |
dc.contributor.author | Skoczyńska, Anna | en |
dc.contributor.author | Stefanelli, Paola | en |
dc.contributor.author | Taha, Muhamed-Kheir | en |
dc.contributor.author | Toropainen, Maija | en |
dc.date.accessioned | 2022-11-07T23:38:25Z | - |
dc.date.available | 2022-11-07T23:38:25Z | - |
dc.date.issued | 2019 | en |
dc.identifier.citation | 37, (7), 2019, p. 991-1000 | en |
dc.identifier.other | RIS | en |
dc.identifier.uri | http://dora.health.qld.gov.au/qldresearchjspui/handle/1/3083 | - |
dc.description.abstract | Background: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine.; Methods: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England.; Results: Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%.; Conclusions: gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates. (Copyright © 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.. All rights reserved.)Date of Electronic Publication: 2019 Jan 17. Current Imprints: Publication: Amsterdam, The Netherlands : Elsevier Science; Original Imprints: Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- <br /> | en |
dc.language.iso | en | en |
dc.relation.ispartof | Vaccine | en |
dc.title | Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide | en |
dc.type | Article | en |
dc.identifier.doi | 10.1016/j.vaccine.2018.12.061 | en |
dc.subject.keywords | Global Health | en |
dc.subject.keywords | Humans | en |
dc.subject.keywords | Meningitis, Meningococcal/epidemiology | en |
dc.subject.keywords | Molecular Epidemiology/methods | en |
dc.subject.keywords | Neisseria meningitidis, Serogroup B/genetics | en |
dc.subject.keywords | Neisseria meningitidis, Serogroup B/isolation & purification | en |
dc.subject.keywords | 4CMenB vaccine* | en |
dc.subject.keywords | Genotyping* | en |
dc.subject.keywords | Neisseria meningitidis serogroup B* | en |
dc.subject.keywords | Strain coverage* | en |
dc.subject.keywords | gMATS* | en |
dc.subject.keywords | Meningococcal Vaccines/*immunology | en |
dc.subject.keywords | Meningitis, Meningococcal/*microbiology | en |
dc.subject.keywords | Genotyping Techniques/*methods | en |
dc.subject.keywords | Genotype*Antigens, Bacterial/*genetics | en |
dc.subject.keywords | Neisseria meningitidis, Serogroup B/*classification | en |
dc.relation.url | https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=30661831&site=ehost-live | en |
dc.identifier.risid | 3668 | en |
dc.description.pages | 991-1000 | en |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
Appears in Sites: | Children's Health Queensland Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.